Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1338574 | 0.78 | LIMK1 (0.40) | MAPK1KDM4EALDH1A1 | |
| SCHEMBL27846918 | 0.78 | ALDH1A1 (0.36) | MAPK1KDM4EALDH1A1 | |
| SCHEMBL1338519 | 0.75 | CHUK (0.32) | MAPK1KDM4EALDH1A1 | |
| SCHEMBL1338496 | 0.75 | MAPK1 (0.32) | MAPK1KDM4EALDH1A1 | |
| SCHEMBL28793921 | 0.75 | MAPK1 (0.32) | MAPK1KDM4EALDH1A1 | |
| SCHEMBL1338489 | 0.75 | MAPK1 (0.34) | MAPK1KDM4EALDH1A1 | |
| SCHEMBL27687020 | 0.75 | ALDH1A1 (0.36) | MAPK1KDM4EALDH1A1 | |
| SCHEMBL1338549 | 0.68 | MAPK1 (0.39) | MAPK1KDM4EALDH1A1 | |
| SCHEMBL17601527 | 0.61 | CSNK1A1 (0.53) | KDM4EALDH1A1 | |
| SCHEMBL24307868 | 0.60 | OPRK1 (0.40) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102282144-A | Oxadiazole derivatives as sphingosine-1-phosphate 1 receptor agonists | — | 2011-12-14 | — | — | CN | disclosed |
| US-20110274657-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2011-11-10 | — | — | US | disclosed |
| US-20110274657-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2011-11-10 | — | — | US | disclosed |
| US-20110274657-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2011-11-10 | — | — | US | disclosed |
| EP-2210890-A1 | Oxadiazole derivatives as S1P1 receptor agonists | Almirall, S.A. (ES) | 2010-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110274657-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS | S1PR1, S1PR3, S1PR2 | MAPK1 1697/4885MAP3K12 2424/4885KDM4E 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.